Notes from the Field

Pediatric Emergency Department Visits for Buprenorphine/Naloxone Ingestion — United States, 2008–2015

Daniel S. Budnitz, MD; Maribeth C. Lovegrove, MPH; Mathew R.P. Sapiano, PhD; Justin Mathew, PharmD; Scott R. Kegler, PhD; Andrew I. Geller, MD; Christian Hampp, PhD

Expanding access to office-based medication-assisted treatment with buprenorphine/naloxone for opioid dependence is a key part of the national strategy to address the opioid abuse epidemic (1). However, as buprenorphine/naloxone prescribing increased, emergency department (ED) visits and hospitalizations for unsupervised ingestions by young children began to increase, with buprenorphine/naloxone ingestions becoming the most common cause of hospitalization for medication ingestions by young children during 2010–2011 (2). Buprenorphine ingestions might be asymptomatic or can cause drowsiness, vomiting, or respiratory depression, which if untreated can result in death (3). Buprenorphine/naloxone was available only as tablets in multidose child-resistant bottles (Suboxone) until late 2010, when film strips packaged in unit-dose, child-resistant pouches were introduced. In 2013, tablets became available in unit-dose packaging (Zubsolv). Because unit-dose, child-resistant packaging encloses each dose until opened, it might limit unintended ingestions by young children compared with traditional child-resistant bottles that must be resecured after every use (4).

This study compared ED visits for pediatric buprenorphine/naloxone ingestions before and after these product packaging/formulation changes.

Rates of ED visits for ingestions by children aged <6 years were calculated for the years 2008–2015 from estimates of ED visits for buprenorphine/naloxone ingestions (National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance [NEISS-CADES] project) and dispensed outpatient prescriptions (IMS Health: National Prescription Audit) (5). NEISS-CADES and IMS Health are national samples, with each case or prescription weighted to allow calculation of nationally representative estimates. A two-tailed test was used to evaluate any change in rates over the study period.

The estimated number of dispensed buprenorphine/naloxone prescriptions nearly tripled from 2008 (3,178,571) to 2015 (9,122,150). During 2008–2010, nearly all (97.6%) buprenorphine/naloxone prescriptions were dispensed as tablets in multidose bottles; by 2013–2015, most (86.9%) prescriptions were dispensed as unit-dose packaged tablets or film strips (Figure).

Based on 183 cases, there were an estimated 8,136 (95% confidence interval [CI] = 4,892–11,380) ED visits for buprenorphine/naloxone ingestions by children aged <6 years from 2008–2015. Three fourths of visits (75.4%;
CI = 67.5%–83.2%) involved children aged 1 or 2 years, and half the visits (50.5%; CI = 36.6%–64.5%) involved boys. Most visits required hospitalization (61.6%; CI = 46.7%–76.5%). During 2008–2010, there were an estimated 1,246 ED visits (CI = 662–1,830) annually for buprenorphine/naloxone ingestions by children aged <6 years, compared with an estimated 799 visits (CI = 324–1,274) annually during 2013–2015. Accounting for prescribing frequency, ED visits for unmonitored buprenorphine/naloxone ingestions declined 65.3%, from an estimated 28.2 ED visits per 100,000 dispensed prescriptions during 2008–2010 to an estimated 9.8 per 100,000 dispensed prescriptions during 2013–2015 (p = 0.011).

The approximate two thirds reduction in the rate of ED visits by children for buprenorphine/naloxone ingestions as the proportion of prescriptions dispensed in unit-dose packaging increased to over 80%, suggests that packaging/formulation changes might reduce pediatric ingestions. A study of poison center calls for pediatric buprenorphine/naloxone exposures also found a significantly lower rate of calls involving film strips in unit-dose packaging, compared with tablets in multidose bottles (6). Other factors potentially contributing to the rate reduction include increased counseling of patients on safe use and storage (7) and a decline in pediatric medication ingestions overall (22% from 2010 to 2013) (8).

Although substantially decreased, ED visits for pediatric ingestions of buprenorphine/naloxone were not eliminated after widespread adoption of unit-dose, child-resistant packaging. One explanation might be that some patients using buprenorphine/naloxone for medication-assisted treatment divide doses rather than consuming the entire unit, leaving unused partial doses accessible to children. In addition, the proportion of buprenorphine/naloxone prescriptions dispensed in unit-dose packaging began to decline at the end of 2013, reflecting the introduction of generic buprenorphine/naloxone tablets packaged in multidose bottles. Citing concern for pediatric exposures, the Massachusetts Office of Medicaid made unit-dose packaged products available to those in households with children aged <6 years (9). At least one manufacturer of the generic product has voluntarily transitioned to unit-dose packaging, but others continue to use multidose bottles (7).

To improve access to medication-assisted treatment, the U.S. Department of Health and Human Services nearly tripled the maximum patient limit for buprenorphine prescribers in July 2016 (1). As prescribing increases, and if multidose bottles again become the predominant form of packaging, it will be important to monitor the rate of ED visits for pediatric buprenorphine ingestions and respond if the rate increases.

Acknowledgment

Grace Chai, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration.

References